Cavidine
Cavidine ((+)-Cavidine) is an analgesic and anti-inflammatory agent. Cavidine can be isolated from Corydalis ternata f. yanhusuo (Y.H.Chou & Chun C.Hsu) Y.C.Zhu. Cavidine reduces the expression of inflammatory factors IL-1β, IL-6 and TNF-α, and inhibits calcium ion influx. Cavidine inhibits the phosphorylation of p38 and ERK1/2. Cavidine increases mechanical and thermal pain thresholds in chronic pain models. Cavidine can be used for the research of chronic pain.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 32728-75-9
- 分子式: C21H23NO4
- 分子量:353.41
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
p38 |
ERK1 |
ERK2 |
IL-1β |
IL-6 |
Cavidine (10 μg/mL) inhibits α,β-ME-ATP-induced calcium ion influx in P2X3-overexpressing U373 cells[1].
Cavidine (2.5-10 μg/mL; 24 h) inhibits LPS-induced activation of BV-2 microglial cells[1].
Cavidine (5-10 μg/mL) inhibits α,β-ME-ATP-induced phosphorylation of p38 and ERK1/2 in primary DRG neurons[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cavidine (2.5-10 mg/kg; i.p.; daily) exerts dose-dependent analgesic and anti-inflammatory effects in SNI-induced neuropathic pain mice by downregulating P2X3 receptors, inhibiting microglial activation, suppressing inflammatory factor production, and reducing MAPK pathway activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J (female, 6-9 weeks old, 20-25 g, CFA-induced)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.p.; daily; 7 days
-
Result:Significantly increased paw withdrawal threshold (PWT) and thermal withdrawal latency (TWL) compared to untreated CFA mice (P < 0.05, P < 0.01, or P < 0.001).
Reduced paw swelling compared to untreated CFA mice after 7 days of treatment (P < 0.05 or P < 0.001).
Suppressed DRG protein expression of IL-1β and TNF-α (P < 0.001), while 5 mg/kg and 10 mg/kg suppressed DRG IL-6 protein expression (P < 0.01 or P < 0.001).
Suppressed DRG mRNA expression of IL-6 (P < 0.001); 5 mg/kg and 10 mg/kg suppressed DRG mRNA expression of IL-1β (P < 0.001), and 10 mg/kg suppressed DRG mRNA expression of TNF-α (P < 0.001).
Suppressed spinal cord protein and mRNA expression of IL-1β, TNF-α, and IL-6 (P < 0.05 or P < 0.001).
Reduced spinal cord IBA-1 expression at 5 mg/kg and 10 mg/kg compared to untreated CFA mice (P < 0.05 or P < 0.01).
Reduced inflammatory cell infiltration and attenuated neuronal atrophy in DRG, as well as reduced neuronal vacuolation and glial clusters in the spinal cord compared to untreated CFA mice.
Suppressed DRG and spinal cord P2X3 receptor protein and mRNA expression (P < 0.05, P < 0.01, or P < 0.001).
Reduced DRG p-p38 and p-ERK1/2 phosphorylation at 2.5 mg/kg; 5 mg/kg and 10 mg/kg significantly suppressed both p-p38 and p-ERK1/2 phosphorylation in DRG (P < 0.001).
-
Animal Model:C57BL/6 J (female, 6-9 weeks old, 20-25 g, SNI-induced)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.p.; daily
-
Result:Significantly increased paw withdrawal threshold (PWT) and thermal withdrawal latency (TWL) compared to untreated SNI mice (P < 0.05, P < 0.01, or P < 0.001).
Suppressed DRG protein expression of IL-6 and IL-1β at 5 mg/kg and 10 mg/kg (P < 0.001), while 10 mg/kg suppressed DRG TNF-α protein expression (P < 0.01).
Suppressed spinal cord TNF-α protein expression at 2.5 mg/kg (P < 0.001); 5 mg/kg and 10 mg/kg suppressed spinal cord protein expression of TNF-α, IL-6, and IL-1β (P < 0.001).
Suppressed DRG mRNA expression of TNF-α (P < 0.001); 5 mg/kg and 10 mg/kg suppressed DRG mRNA expression of IL-6 and IL-1β (P < 0.01 or P < 0.001).
Suppressed spinal cord mRNA expression of IL-6 and IL-1β (P < 0.01 or P < 0.001); 5 mg/kg and 10 mg/kg suppressed spinal cord TNF-α mRNA expression (P < 0.01 or P < 0.001).
Reduced spinal cord IBA-1 expression at 5 mg/kg and 10 mg/kg compared to untreated SNI mice (P < 0.05 or P < 0.01).
Reduced inflammatory cell infiltration and attenuated neuronal atrophy in DRG, as well as reduced neuronal vacuolation and glial clusters in the spinal cord compared to untreated SNI mice.
Suppressed DRG and spinal cord P2X3 receptor protein expression at 5 mg/kg and 10 mg/kg (P < 0.05 or P < 0.01); all doses suppressed DRG and spinal cord P2X3 receptor mRNA expression (P < 0.001).
Reduced DRG p-p38 phosphorylation at 2.5 mg/kg; 5 mg/kg and 10 mg/kg significantly suppressed both p-p38 and p-ERK1/2 phosphorylation in DRG (P < 0.001).
化学情報
-
CAS 番号 32728-75-9
-
分子量 353.41
-
分子式 C21H23NO4
-
SMILES
C[C@H]1C(C=C2)=C(C3=C2OCO3)CN4CCC5=CC(OC)=C(OC)C=C5[C@@]14[H]
-
別名
(+)-Cavidine
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Cavidine 関連分類
HY-101546A 関連分類
Powered by Bioz